Argenx SE annual ebitda
2022
2023
2024
2025
Argenx SE EBITDA Growth & History (ARGX)
Argenx SE's calculated EBITDA was $1.31B for fiscal 2025.
View full Argenx SE company overviewArgenx SE annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.31B | $1.21B | +1146.34% |
| 2024 | 2024-12-31 | $105.2M | $297.5M | — |
| 2023 | 2023-12-31 | −$192.3M | $430.5M | — |
| 2022 | 2022-12-31 | −$622.8M | — | — |
Argenx SE quarterly ebitda
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $533.0M | $245.0M | +85.05% |
| Q1 2026 | 2026-03-31 | $427.0M | — | — |
| Q4 2025 | 2025-12-31 | $404.1M | — | — |
| Q3 2025 | 2025-09-30 | $387.0M | — | — |
| Q2 2025 | 2025-06-30 | $288.0M | — | — |
Argenx SE ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Argenx SE's ebitda increased from −$622.8M to $1.31B, a change of $1.93B. The latest reported quarter, Q2 2026, shows $533.0M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Argenx SE source filings ↗Community posts
Argenx sales expand as additional clinical and regulatory work advances
Argenx ($ARGX) reported third-quarter 2026 product sales of approximately $1.7 billion, an increase of 54% from a year earlier and 13% from the preceding quarter. Net profit attributable to shareholders increased to $506 million from $344 m ...
